Recent performance swings in ADMA Biologics (ADMA) have put fresh attention on what investors are paying for its plasma-derived therapies business after a year of sharp declines and a much stronger past 3 months.
The recent rebound in ADMA Biologics, with a 12.07% 90‑day share price return, contrasts sharply with a year‑to‑date share price decline of 47.54%, while a very large 5‑year total shareholder return of about 7x signals that long‑term holders have seen substantial gains.
Scan beyond ADMA Biologics and see how other plasma and healthcare specialists with strong balance sheets are setting up right now in our list of solid balance sheet and fundamentals (24 results) .
ADMA Biologics now trades at US$9.38 while consensus points to US$17, and intrinsic estimates imply an even steeper gap. Are investors looking at a temporary swing or a lasting discount to fair value?
Most Popular Narrative: 47% Undervalued
On the most followed view, ADMA Biologics screens as materially undervalued, with a fair value of $17.60 against the latest $9.38 close, and the gap is tied directly to how the plasma economics and capacity story play out over time.
Commercial-scale implementation of the FDA-approved yield enhancement process is producing a 20%+ increase in bulk immunoglobulin output, expected to drive sustained gross margin expansion and higher net income starting in early 2026 and beyond.
See why 47 investors see ADMA Biologics as 47% undervalued .
Result: Fair Value of $17.60 (UNDERVALUED)
Still, the class action lawsuits and questions around ASCENIV channel stuffing and related party dealings could pressure sentiment on ADMA Biologics if disclosures disappoint investors.
Find out about the key risks to this ADMA Biologics narrative .
Next Steps
Mixed messages in the ADMA Biologics story make this a good moment to stress test the numbers yourself and decide how compelling the opportunity feels. To see what the optimistic investors are focusing on, review the 3 key rewards .
Looking for more ADMA Biologics style investment ideas?
If ADMA Biologics has sharpened your focus on pricing gaps and fundamentals, do not stop here. Use curated screeners to spot the next candidates before the crowd moves in.
-
Target resilience by reviewing companies that show strong balance sheets and solid fundamentals in our list of solid balance sheet and fundamentals (24 results) .
-
Hunt for value by checking out 32 high quality undervalued stocks that combine quality metrics with pricing that still looks compressed.
-
Zero in on potential future leaders by scanning 16 high quality undiscovered gems that pair robust fundamentals with limited current market attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ADMA .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
